-
Healthcare Professionals
-
Therapies and Procedures
-
Concomitant Surgical Ablation Therapy
- Ablation Sensing Unit & Switch Matrix
- cryoFORM® Cryoablation Probe
- cryoICE® BOX V6
- cryoICE® Cryoablation Probes
- Isolator® Linear Pen
- Isolator® Synergy™ Access® Clamp
- Isolator® Synergy™ Clamps (OLL2/OSL2)
- Isolator® Transpolar Pen (MAX3)
- Isolator® Synergy™ EnCompass® Clamp
- Multifunctional Ablation Generator (MAG)
- Hybrid AF™ Therapy
- Hybrid Total Thoracoscopic Therapy
- Left Atrial Appendage Management
- Cryo Nerve Block Therapy
-
Concomitant Surgical Ablation Therapy
- Education & Training
- Clinical Evidence
- Product Labeling
- Resources
- Society Guidelines
-
Therapies and Procedures
- Patients & Caregivers
- About AtriCure
News
MASON, Ohio --(BUSINESS WIRE)--Jun. 1, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, announced the appointment of Deborah Yount as Chief
MASON, Ohio --(BUSINESS WIRE)--Jun. 15, 2021-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Deborah H. Telman and Maggie Yuen have been elected to its Board of Directors. Ms.
© 2026 Atricure, Inc. All Rights Reserved.
